Epigenetic alterations in endocrine-related cancer

Sandra Rodríguez-Rodero1,2, Elías Delgado-Álvarez1, Agustín F Fernández2, Juan L Fernández-Morera1, Edelmiro Menéndez-Torre1 and Mario F Fraga2,3

1Endocrinology and Nutrition Service, Hospital Universitario Central de Asturias, Av. Julian Clavería s/n, 33006 Oviedo, Spain
2Cancer Epigenetics Laboratory, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain
3Department of Immunology and Oncology, National Center for Biotechnology, CNB-CSIC, Cantoblanco, Madrid E-28049, Spain

Abstract

Aberrant epigenetics is a hallmark of cancer, and endocrine-related tumors are no exception. Recent research has been identifying an ever-growing number of epigenetic alterations in both genomic DNA methylation and histone post-translational modification in tumors of the endocrine system. Novel microarray and ultra-deep sequencing technologies have allowed the identification of genome-wide epigenetic patterns in some tumor types such as adrenocortical, parathyroid, and breast carcinomas. However, in other cancer types, such as the multiple endocrine neoplasia syndromes and thyroid cancer, tumor information is limited to candidate genes alone. Future research should fill this gap and deepen our understanding of the functional role of these alterations in cancer, as well as defining their possible clinical uses.

Key Words

- multiple endocrine neoplasias
- neuroendocrine tumors
- oncology
- pathogenesis

Introduction

Epigenetics is defined as the study of those stable genetic modifications that result in changes in function and gene expression without altering the DNA sequence. The term was first described in 1942 by C H Waddington as the study of how genotypes give rise to phenotypes through programmed changes during development (Waddington 1942).

Epigenetic mechanisms refer to changes in the interaction between DNA and histones, which influences the degree of compaction of chromatin, allowing the genome to be differentially manifested depending on the stage of development, the type of tissue, or the existence of disease. Among these mechanisms, DNA methylation and histone post-translational modifications coexist with histone variants, chromatin remodelers, small non-coding RNA molecules, and polycomb and trithorax complexes. However, all such mechanisms in fact cooperate with each other, and also with other levels of regulation, to establish and maintain chromatin in either a condensate or non-condensate state, which ultimately determines gene expression profiles. In this review, we focus exclusively on DNA methylation and histone modifications.

DNA methylation is the most studied epigenetic mechanism to date and occurs in ~3% of cytosines, which precede guanines as part of the so-called cytosine–guanine dinucleotides (CpGs) present in the genome (Hermann et al. 2004). Recently, non-CpG methylation in stem cells has been described and it seems not to be directly associated with transcriptional repression, but rather to be associated with maintaining a pluripotent state (Lister et al. 2009).

Some CpG sites in the genome are concentrated on the so-called ‘CpG islands’ located around 200 bp
at several kb from the transcription start site of a gene (Antequera 2003). These CpG islands are present in 60% of genes and are usually non-methylated, except in those genes subject to genomic imprinting, X chromosome inactivation, or tissue-specific repression (Antequera 2003). By contrast, those CpG dinucleotides that are located mainly in the bodies of genes, intergenic regions, repetitive sequences, and transposons (Martin-Subero 2011, Fedoriw et al. 2012). In the context of CpG islands, DNA methylation is sometimes associated with transcriptional repression, this being an important mechanism of gene regulation. DNA methylation can promote greater condensation of chromatin, preventing the access of transcription machinery. It has been proposed that, when CpG sites are part of non-coding, repetitive sequences and transposons, the role of methylation is to preserve chromosome stability by preventing the reactivation of mobile elements and maintain the integrity of chromosomes (Bird 2002).

Through the maintenance of chromosomal stability and the regulation of gene expression, DNA methylation is crucial for processes such as cell differentiation and embryonic development (Fedoriw et al. 2012). It is carried out by a group of enzymes known as DNA cytosine-S-methyltransferases (DNMTs), which transfer the methyl group from S-adenosylmethionine (SAME) to the C5 position of cytosine. In mammals, five DNMTs have been described, of which only three are active: DNMT1 is primarily involved in the maintenance of methylation patterns and has a preference for hemi-methylated DNA, which is frequently located at DNA replication sites during the cell cycle (S phase) (Qin et al. 2011). DNMT3A and DNMT3B are known as the ‘de novo DNMTs,’ as they seem to possess the ability to establish profiles of DNA methylation and do not discriminate between hemi-methylated and unmethylated DNA (Chedin 2011); although further studies have demonstrated that both types of enzymes play a role in the maintenance of methylation as well as in methylation-dependent repression of specific oncogenes in cancer cells (Fernandez et al. 2012). These enzymes determine the overall methylation profiles in the early stages of embryonic development in germ cells and cooperate in the establishment and maintenance of DNA methylation profiles (Fatemi et al. 2002).

Histones have an amino-terminal tail consisting of 20–35 amino acid residues, with a highly conserved sequence that is susceptible to modifications such as acetylation, methylation, phosphorylation, ubiquitination, sumoylation, and ADP-ribosylation. These are, in the majority, dynamic and reversible changes. The enormous variety of potential modifications and their possible combinations generate a wide range of functional responses known as the ‘histone code’. Histones play a role in the establishment of structural domains of chromatin and the regulation of DNA functions such as transcription, repair, replication, and condensation of chromosomes. Two of the best-studied modifications are the acetylation and methylation of histones. The former is carried out by histone acetyltransferases (HATs) and reversed by histone deacetylases (HDACs), while the latter is thought to take place at the lysine and arginine residues and can incorporate one to three methyl groups for each residue (Zhang et al. 2012).

At the transcriptional level, the effect of methylation varies as a function of its extent and the specific residue affected and is also involved in establishing chromatin structural domains. The enzymes responsible for this modification are known as histone methyltransferases (HMTs), substrate specific, and employ SAME as a donor of methyl groups, while the reverse process is carried out by histone demethylases (Li et al. 2012).

**Epigenetic alterations in tumors of the endocrine system**

In the last 20 years, advances in the field of endocrine oncology have enabled the genetic basis of some hereditary endocrine tumors to be uncovered, and they have also contributed to increasing knowledge of certain sporadic diseases, and consequently the development of new diagnosis or treatment methods. In addition, the contribution of epigenetic mechanisms in tumor development has been widely described.

In this review, we focus on those endocrine tumors where the role of certain epigenetic mechanisms (DNA methylation and histone modifications) has been demonstrated. Endocrine tumors affect parts of the body that secrete hormones and include adrenal gland tumor (adrenocortical carcinoma, ACC), islet cell tumors (gastrinoma, VIPoma, glucagonoma, and somatostatinoma), neuroendocrine tumors (such as pheochromocytoma), parathyroid and thyroid carcinomas, among others. In the following sections, for the purpose of discussion, these endocrine tumors will be divided into those which are hereditary (multiple endocrine neoplasia (MEN) syndromes) and those which are sporadic (thyroid, parathyroid, breast and ovarian, prostate, adrenocortical, and lung neuroendocrine tumors and pheochromocytoma, and paraganglioma).
Hereditary endocrine tumors

The MEN syndromes  MEN syndromes predispose people to develop endocrine tumors. The major glands affected by the MEN syndromes are the pituitary, thyroid, parathyroid, adrenal, and pancreas. There are two different MEN syndromes, MEN1 and MEN2, which are similar although there are important differences.

MEN1 syndromes (prevalence of 3/10 000) are characterized by the development of tumors of the parathyroid, pituitary glands, and the pancreas (Thakker et al. 2012).

The genetic mutation responsible for MEN1 spans 9.8 kb of chromosome 11q13 (Chandrasekharappa et al. 1997). Germ line mutations in MEN1 have been found in the vast majority of MEN1 kindreds, and somatic MEN1 mutations have also been reported in sporadic parathyroid adenomas, pituitary and lung tumors, insulinomas, and gastrinomas (Debelenko et al. 2000, Hasani-Ranjbar et al. 2011, Delemer 2012). The protein product of MEN1, termed menin, is a tumor suppressor protein ubiquitously expressed in the nucleus. It has not only been reported to interact with transcription factors such as JunD, Smad3, and p27, and, as a transcriptional coactivator, promotes histone methylation of specific target genes that govern neuroendocrine cell growth and differentiation, in a similar way to that described in leukemogenesis (Chang et al. 2011, Murai et al. 2011, Thiel et al. 2012; Table 1).

Insulinomas are extremely rare but are the most common neuroendocrine tumors associated with MEN1 in the pancreas: seldom malignant they are derived from β-cells with an uncontrolled secretion of insulin that results in hypoglycemia (Mathur et al. 2009). The work developed by Karnik et al. (2005) demonstrated that in pancreatic endocrine cells menin interacts with p27 (Cdkn1b) and p18 (Cdkn2c) promoters; two cyclin-dependent kinase inhibitors that play an important role in islet growth control. Menin, through MLL2 interaction, regulates the HMT activity of this TrxG complex member and, as a transcriptional coactivator, promotes histone methylation of p27 and p18. Men1 inactivation disrupts p27 and p18 expression and alters islet growth control and

Table 1  Epigenetic alterations in endocrine tumors

<table>
<thead>
<tr>
<th>Endocrine neoplasia</th>
<th>Epigenetic alteration</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary endocrine tumors</td>
<td>Menin interaction with the trithorax proteins MLL2 and MLL, with histone H3 lysine H4 methyltransferase activity</td>
<td>Murai et al. (2011)</td>
</tr>
<tr>
<td>Multiple endocrine neoplasia 1 (MEN1)</td>
<td>Aberrant promoter methylation in RASSF1A</td>
<td>Schagdarsurengin et al. (2002)</td>
</tr>
<tr>
<td>Multiple endocrine neoplasia 2 (MEN2)</td>
<td>Aberrant promoter methylation in RASSF1A, PTEN, RASSF2, and RASSF10</td>
<td>Porra et al. (2005), Brzezianska &amp; Pastuszak-Lewandoska (2011) and Brait et al. (2012)</td>
</tr>
<tr>
<td>Sporadic endocrine tumors</td>
<td>Aberrant promoter methylation in TIMP3, SLC5A8, and DAPK</td>
<td>Juhlin et al. (2010) and Svedlund et al. (2012)</td>
</tr>
<tr>
<td>Thyroid tumors</td>
<td>Aberrant promoter methylation in H1C1 and RASSF1</td>
<td>Nass et al. (2000), Lindqvist et al. (2012), Wang et al. (2012) and Xu et al. (2012)</td>
</tr>
<tr>
<td>Parathyroid tumors</td>
<td>Aberrant promoter methylation in BRCA1, ERα, p16, RASSF1A, and SLC25A43</td>
<td>Dhillon et al. (2004a,b)</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Aberrant promoter methylation in BRCA1, BRCA2, FHIT, FANCE, and p16</td>
<td>Kang et al. (2004), Verdoordt et al. (2011) and Mahapatra et al. (2012)</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>Aberrant promoter methylation in GSTP1, MGMT, p16, CDH1, and RASSF1A</td>
<td>Gao et al. (2010) and Park et al. (2012)</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Aberrant promoter methylation in p16, SPARC, and TFPI2</td>
<td></td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Enriched methylation in H3K9 markers of MUC1 and MUC2 gene promoter</td>
<td></td>
</tr>
<tr>
<td>Adrenocortical cancer</td>
<td>Genome-wide methylation profiles</td>
<td>Rechache et al. (2012) and Barreau et al. (2013)</td>
</tr>
</tbody>
</table>

MLL2, mixed lineage leukemia; RASSF1, Ras-association domain family; PTEN, phosphatase and tensin homolog; TIMP3, TIMP metalloproteinase inhibitor; SLC5A8, solute carrier family; DAPK, death-associated protein kinase; H1C1, breast cancer 1; FHIT, fragile histidine triad protein; FANCE, Fanconi anemia gene F; GSTP1, glutathione S-transferase P1; MGMT, O-6-methylguanine DNA methyltransferase; CDH1, E-cadherin gene; SPARC, secreted protein, acidic, cysteine-rich (osteonectin); TFPI2, tissue factor pathway inhibitor 2; MUC2, mucin gene 2.
tumor suppression. Moreover, Fontanière et al. (2008) have demonstrated in a mice model that Men1 disruption was not enough to trigger tumorigenesis of β-cells and that the gene expression profile of insulin-like growth factor (Igf) was also deregulated. They showed that Igf2 was overexpressed in Men1 mutant mice, as in other abnormal B-cell proliferations (Vasavada et al. 2006) as well as in insulinomas (Hoog et al. 2001), and that this overexpression is a consequence of the hypermethylation of the intragenic differentially methylated regulatory regions (DMR2) of the Igf2 gene, which increases the level of transcription through this epigenetic mechanism.

Pituitary tumors occur in 54–80% of patients with MEN1 syndrome, and prolactinoma is the most common one (41–76%). Yoshino et al. (2007) showed promoter hypermethylation at least at one of the cell cycle regulator genes (RB1, P14ARF, P15 (INK4b) (CDKN2B), P16 (CDKN2A), P21 (CDKN1A), P27, and P73 (TP73)) in pituitary tumors. Interestingly, genes of the RB1 pathway were methylated in 85% of the samples, which suggests that, in addition to MEN1 mutations, methylation could be a molecular alteration that contributes to these tumors. These results were also confirmed by Bello et al. (2006), who found promoter hypermethylation in the RB1, P14 (ARF), P16, and P73 genes, as well as the metalloproteinase inhibitor 3 (TIMP3), O-6-methylguanine DNA methyltransferase (MGMT), DAPK (DAPK1), THBS1, and CASP8 genes, some of which are involved in the apoptosis processes (DAPK and CASP8), DNA repair (MGMT) or have anti-angiogenic properties (THBS1). Additionally, reduced expression of the fibroblast growth factor receptor (FGFR2), a member of the FGF family with a critical role in pituitary development, in human pituitary tumors has been associated with gene promoter methylation (Zhu et al. 2007).

The MEN2 is characterized by a very high risk (95%) of developing medullary thyroid cancer (MTC). It is divided into three clinical subtypes: MEN2a, MEN2b, and familial medullary thyroid carcinoma (FMTC). MEN2a was characterized by the presence of MTC at the beginning of adulthood (50%), phaeochromocytoma, and parathyroid hyperplasia (no adenomas) (20–30%). Parathyroid hyperplasia does not, however, develop in MEN2b, which is characterized by MTC in early childhood and phaeochromocytomas (often 50%). FMTC affects several members of the same family, where phaeochromocytoma and hyperparathyroidism are not present. MTC originates from C-cells, which are derived from the neural crest, secrete calcitonin (CTN), and glycoprotein carcinoembryonic antigen (CEA). Mutations in the RET proto-oncogene, which encodes a tyrosine kinase receptor, have been described as the main cause of MEN2a, MEN2b, and FMTC.

Moreover, promoter methylation of RASSF1A (RASSF1) could also be involved in thyroid cancer development due to its high incidence in MTC (85%) (Schagdarsurengin et al. 2002). RASSF1 encodes a signaling protein (tumor suppressor) that functions through a pathway involving RAS, a component of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, and is mainly inactivated by methylation (Brait et al. 2012). This phenomenon is more frequent in those tumors that develop distant metastasis and is also found in the more aggressive forms of MTC (Table 1).

**Sporadic endocrine diseases**

**Thyroid tumors** The thyroid tumors can be classified by their degree of clinical aggressiveness: the least aggressive forms include papillary thyroid carcinomas (PTCs), the most frequent form (50–90%), which can metastasize early in the cervical lymph nodes, and follicular thyroid carcinomas (FTCs), which spread primarily by hematogenous dissemination; the MTC, which causes early metastasis (lung and bone) originating both via the lymph and blood; and the most aggressive, anaplastic thyroid carcinomas (ATCs) with early distant metastasis. Gene promoter methylation of tumor suppressor genes such as CDH1, PTEN, RASSF1A, and FGFR2 has been described as part of the pathology of the thyroid tumors (Table 1). The PTEN gene encodes phosphatase that blocks the signaling of the PI3K/Akt pathway, which is constitutively activated in FTCs. The RASSF1A, RASSF2, and Ras-association domain family signaling protein (RASSF10) genes are methylated in PTCs, FTCs, and ATCs. RAS is a component of the PI3K/Akt pathway, suggesting a relationship between PTEN and RAS proteins in the development of this pathology (Schagdarsurengin et al. 2009, 2010, Brzezińska & Pastuszak-Lewandoska 2011).

Other tumor suppressor genes TIMP3, SLC5A8, and DAPK are also aberrantly regulated by methylation in thyroid tumors (Porra et al. 2005, Brait et al. 2012). TIMP3 is a tissue inhibitor of metalloproteinases with important roles in inhibiting angiogenesis, invasion, and metastasis, which limits the spread of tumoral cells (Anania et al. 2011). SLC5A8, a member of the sodium solute symporter family (SLC5), and DAPK, a calcium/calmodulin-dependent serine–threonine kinase, both exert proapoptotic activity, which suggests the possibility that their inactivation could block apoptotic processes, and thus facilitate invasion of the tumor cells in PTCs. These results reveal
the importance of DNA methylation in the regulation of this gene expression and point to its possible functional role in thyroid cancer.

Recently, our group has developed genome methylation profiling of thyroid cancer, allowing the description of differential DNA methylation patterns for the differentiated and the non-differentiated subtypes. These latter subtypes are characterized by aberrant promoter hypomethylation, which could be used in diagnosis and/or prognosis of this type of cancer (Rodriguez-Rodero et al. 2013).

**Parathyroid tumors** Parathyroid tumors are an abnormal growth in the parathyroid gland and usually cause hyperparathyroidism. Most of them are benign adenomas (85%) and carcinomas are very rare (0.5–1%). Overexpression of CCND, and deletions of the RB1 gene or BCRA2 genes on chromosome 13, has been identified as a possible cause of these tumors (Shattuck et al. 2003, Mallya et al. 2010).

Promoter hypermethylation of the tumor suppressor gene, hypermethylated in cancer 1 (HIC1), has been shown to be frequently repressed in parathyroid cancer (Svedlund et al. 2012). A growth-regulatory role has been assigned to HIC1 in the parathyroid glands and it is suggested that its downmodulation might be an early event in tumoral transformation, where, in addition to DNA methylation, other epigenetic mechanisms such as repressive histone marks (H3K27me2/3) play a part (Table 1).

Similar to thyroid tumors, promoter hypermethylation in RASSF1 and APC genes has also been described in parathyroid carcinomas (Juhlin et al. 2010, Sulaiman et al. 2013). A differential methylation pattern compared with normal parathyroid tissue was observed in parathyroid adenomas (367 genes were significantly altered) and parathyroid carcinomas (175 genes) (Starker et al. 2011). In addition, CDKN2B, P16, WT1, SFRP1, SFRP2, and SFRP4 were hypermethylated in parathyroid carcinomas and showed reduced expression, which was reverted by 5-aza-2’-deoxycytidine, a demethylating agent, demonstrating the importance of alterations in cell cycle regulation in parathyroid tumors (Starker et al. 2011).

**Breast cancer** There are two main types of breast cancer: ductal carcinoma, which is the most common form, and lobular carcinoma. Breast cancer is a heterogeneous disease caused by interactions between inherited and environmental risk factors that lead to the progressive accumulation of genetic and epigenetic changes in breast cells, where a family history of breast cancer is the strongest risk factor for the disease (20%).

The role of epigenetic processes in breast cancer has been widely reported (Bediaga et al. 2010, Huang et al. 2011; Table 1). Methylation of the BRCA1 gene promoter has been described in sporadic breast tumors and has also been suggested as a prognosis factor as it is more frequent in the invasive forms of breast cancer (Bosviel et al. 2012). A relationship between BRCA1 hypermethylation and tumor stage was also described in ovarian cancer, the gene being hypermethylated in stages II and III when compared with stage I, which supports the idea that loss of BRCA1 expression is correlated with a more advanced stage of ovarian cancer (Wang et al. 2013) and suggests the potential of this gene as a biomarker for ovarian and breast cancers.

Many breast cancers are sensitive to the hormone estrogen, which can contribute to tumor development. Those cancers with estrogen receptors (ERs) on the surface of the cancer cells are termed ER-positive. The estradiol in the mammary gland comes from ovarian synthesis, external glandular tissues (i.e., fat deposits), and the mammary gland itself. This hormone exerts mitogenic effects on breast cells leading to neoplastic transformation by increasing the rate of cell proliferation (Berstein et al. 2010). The activities of estrogens are mediated by the two intracellular ERs, ERα and ERβ, which are encoded by the genes ESR1 and ESR2, respectively, and function as transcription factors to regulate gene expression. ERα is expressed in the great majority of breast tumors (75%) (ERα-positive) and frequently associated with a better prognosis and responsiveness to hormone treatment, while ERα-negative breast tumors are associated with a poorer prognosis and a greater malignancy (Xie et al. 2012). One mechanism involved in suppressing ERα expression in ER-negative tumors is aberrant methylation of CpG islands at the ERα promoter, which is present more frequently in metastatic tumors (associated with adverse clinical outcomes) and may represent a key mechanism to hormone resistance (Nass et al. 2000). This negative prognosis of ER-negative tumors could also be mediated by the downregulation of the metastasis tumor antigen 1 (MTA1) gene (observed when breast cancer-invasive cell lines were treated with demethylating agents), which permits the expression of ERα (Mao et al. 2012). The role of this protein in tumor aggressiveness has been confirmed by its role in inducing the pulmonary metastasis in breast cancer (Pakala et al. 2013). Moreover, ERs work in conjunction with HATs and JMJD2B, a histone lysine-specific demethylase. Distal to the ER-binding site is an
enrichment of H3K9me3 that acts as a repressive marker of transcription. Upon 17β-estradiol activation, JMJD2B expression is induced, and it is recruited to ERα target sites and demethylates H3K9me3. Moreover, this interaction with the receptor also allows the recruitment of histone-modifying enzymes, such as HATs, to facilitate the transcription of ER-responsive genes such as MYB, MYC, or CCND1 (which alter cell cycle progression and may contribute to tumorigenesis), which could increase breast cell division and promote tumor growth (Shi et al. 2011).

Other tumor suppressor genes such as P16 and RASSF1A or solute carrier family 25A member 43 (SLC25A43) have also been found hypermethylated in breast cancer (Lindqvist et al. 2012, Wang et al. 2012, Xu et al. 2012); RASSF1A in particular could be used as a prognostic marker in the diagnosis of breast cancer (Lindqvist et al. 2012, Wang et al. 2012, Xu et al. 2012), and its role in cancer has also been described (see earlier sections) in non-small cell lung and thyroid tumors. Recently, Faryna et al. (2012) have demonstrated higher methylation in BCAN, HOXD1, KCTD8, KLF11, NXP1H, POU4F1, SIM1, and TCF7L1 genes in low-grade breast tumors. These results were confirmed by the findings of van Hoesel et al. (2013), which demonstrated an increase in promoter methylation in methylated-IN-tumor 17 (MINT17), MINT31, RARβ2 (RARB), and RASSF1A genes, associated with a poor prognosis of the disease.

**Ovarian cancer** Stromal tumors (frequency <3%) arise from structural cells that hold the ovary together and produce the female hormone estrogen. They often produce estrogen and inhibit A and B. They produce androgens (male hormones) less frequently. Dhillon et al. found promoter methylation in a group of genes: FHIT (28%), a tumor suppressor gene also hypermethylated in other tumor subtypes; FANCF (24%), which interacts with BRCA1 and BRCA2 pathways; CCND2 (12%), involved in the regulation of transition from G1-phase to S-phase during the cell cycle and seemingly exerts a function as tumor suppressor gene in this type of cancer; BCRA2 (4%), which may play a role in the regulation of the cell cycle during proliferation and differentiation; and RUNX3 (56%), which belongs to the RUNT domain genes and also plays a tumor suppressor role (Dhillon et al. 2004a; Table 1).

Dhillon et al. (2004b) also showed promoter hypermethylation in P16, BRCA1, RASSF1A, ERα (ESR1), TMS1 (PYCARD), TMP3, TWIST (TWIST1), GSTP1, androgen receptor (AR), and human MLH1 genes in ovarian cancer. TMP3, which is thought to suppress primary tumor growth, is also downregulated in prostate cancer by methylation and histone methylation (Shinojima et al. 2012). In sporadic breast tumors, P16, MGMT, VHL, MLH1, and BRCA1 have also been shown to be important as prognostic factors (Bosviel et al. 2012), and all are DNA repair and tumor suppressor genes that have been demonstrated to be epigenetically inactivated by DNA methylation in cancers. RASSF1A hypermethylation is associated with a shorter recurrence time, in ovarian, or thyroid tumors (Schagdarsurengin et al. 2009, 2010, Buckingham et al. 2010, Brzezianska & Pastuszak-Lewandoska 2011). P16 silencing, by this epigenetic mechanism, seems to be an early event in the development and progression of ovarian cancers (Dhillon et al. 2004b).

**Prostate cancer** This is the second most frequent tumor in men (accounting for 11.7% of all male tumors). Prognosis improves with early detection (PSA antigen), and an estimated 58% of tumors are diagnosed at an early stage. Among the etiological causes of the disease are environmental and dietary factors (high-fat diet and excess weight), hormonal factors (androgens play an important role in the initiation and promotion of prostate cancer), and genetic factors such as the BRCA2 gene or ELAC2 (individuals with affected relatives, respectively, have a 3.1 and 4.3 times higher risk when compared with healthy controls) (Wallner et al. 2011). The majority of prostate tumors are adenocarcinomas, while <1% are neuroendocrine tumors (Cohen 2005). Valentini et al. (2007) demonstrated that when human prostate androgen-dependent cancer cell line LNCaP was treated with valproic acid, an inhibitor of HDACs, this component induced neuroendocrine-like differentiation in this cell line as well as downregulation of AR protein and reduction in prostate-specific antigen. Moreover, prostate cancer cells commonly exhibit promoter hypermethylation, which causes gene repression in the acquisition and maintenance of the neoplastic phenotype. GSTP1 is the most frequently methylated gene in prostate cancer. Glutathione S-transferases (GSTs) comprise a family of enzymes involved in the detoxification of xenobiotics and oxygen radicals. Absent or diminished expression of the GSTP1 gene in prostate cancer has been reported and is commonly due to CpG island GSTP1 promoter region methylation in the majority of prostate tumors (>90%), a phenomenon that is rarely detected in normal prostate or benign prostatic hyperplasia tissues. This gene has also been described as hypermethylated in breast carcinoma, an early event, which suggests its utility as a biomarker (Mahapatra et al. 2012, Saxena et al. 2012, Fukushima &
Horii 2013, Song et al. 2013). The DNA alkyl-repair gene MGMT, which removes mutagenic and cytotoxic alkyl adducts from genomic DNA, has also been found hypermethylated in this type of tumor (Kang et al. 2004; Table 1).

The prostate responds to sex hormones through specific receptors. The male hormones (testosterone and 5-dihydrotestosterone) exert their actions mediated by the AR. Epigenetic changes, including CpG methylation and histone acetylation, play important roles in the regulation of AR pathway signaling, but the frequency of AR methylation is low in prostate cancer (Nakayama et al. 2000). Estrogens also exert their effect on the prostate through the ERs ER1 and ER2, which are frequently methylated in prostate cancer and correlated with tumor progression (Li et al. 2000). Hypermethylation events in prostate cancer also include genes involved in cell cycle regulation, such as the tumor suppressor gene P16, a cyclin-dependent kinase inhibitor (Verdoordt et al. 2011), or RASSF1A (found in 49–99% of tumors), mentioned in earlier sections, which are also associated with other tumor types and deregulation of which can cause DNA repair failures and Ras-dependent growth control in cancer cells, and which are associated with the most aggressive forms of prostate cancer (Amin & Banerjee 2012). Another hypermethylated tumor suppressor gene in prostate cancer is adenomatous polyposis coli (APC), associated with poor prognosis (Delgado-Cruzata et al. 2012).

Invasion and metastasis are also present in prostate cancer, and some of the genes involved in this process (CDH1, CD44, and TIMP3) are also regulated by promoter methylation: E-cadherin (CDH1), an important member of the cadherin family of cell adhesion molecules, is strongly reduced by promoter methylation in human prostate tumors and disruption of the cell adhesion system can lead to tumor infiltration and metastasis (Li et al. 2001); CD44, which encodes for a protein involved in matrix adhesion (Lou et al. 1999); and tissue inhibitors of metalloproteinases (TIMP3), whose promoter region was found to be methylated in 97% of prostate tumors, allowing MMP expression, tumor growth, invasion, and tumor-induced angiogenesis (Jeronimo et al. 2004).

Hypomethylation is another phenomenon frequently observed in a wide variety of malignancies including prostate cancer (Bedford & van Helden 1987) and could contribute to tumoral transformation through multiple oncogene activation (i.e., MYC and HRAS) and by chromosome instability.

Among the post-translational modifications in histones, methylation of arginine and lysine can be associated with either gene activation or repression. Methylation of lysine 9 in histone 3 (H3K9) is linked to repression of AR target genes, which may include tumor suppressor genes (GAS2, PIK3CG, and ADRB2), and histone H3K4 methylation is associated with AR gene activation. H3K4me1 and H3K4me2 are selectively enriched at the AR enhancers of UBE2C and CDK1 genes (M-phase cell cycle genes) or oncogenes, facilitating AR upregulation of these genes to promote growth, suggesting a role in prostate tumorigenesis. Moreover, increased H3K4me3 in prostate cancer cells correlates with the activation of genes involved in cell growth and survival (i.e., FGFR1 and BCL2), which seem to be responsible for poor clinical outcome in prostate cancer patients (Wissmann et al. 2007, Wang et al. 2009).

Enhancer of zeste homolog 2 (EZH2) has been found overexpressed in prostate cancer, with higher expression in those that are metastatic. This protein is a member of the polycomb repressive complex 2 (PRC2), which causes trimethylation of histone H3 on Lys27 (H3K27) and gene repression. Overexpression of EZH2 seems to be involved in progression and invasion of tumoral cells, through the silencing of tumor repressor genes such as ADRB2, CDH1, PSBP94 (MSMB), and DAB2IP (Ren et al. 2012). Similarly, Rabbio et al. (2012) demonstrated that UHRF1 protein, frequently overexpressed in prostate cancer and other tumors, might play a link role between different epigenetic mechanisms and that it is correlated with poorer prognosis in prostate cancer patients. This protein binds specifically to methylated H3K9 and promotes DNA condensation and gene suppression, and is a strong candidate for a significant role in malignant transformation and tumor progression because its expression is related to downregulation of the tumor suppressor genes ACPP, CBX7, and GAS1 as well as it having a parallel expression to that of EZH2, which would indicate similarity of their roles in tumor progression.

Pancreatic cancer Pancreatic neoplasms arise from the endocrine and exocrine portions of the organ, where the most frequent forms are the ductal adenocarcinomas (exocrine). The pancreatic neoplasms that develop from the endocrine portion include gastrinoma, glucagonoma, VIPoma, somatostatinoma, and insulinoma (see earlier section).

The tumor suppressor gene P16, a cell cycle regulator, is frequently methylated in other tumors such as ovarian tumor (Abou-Zeid et al. 2011, Bammidi et al. 2012) and this promoter methylation was also observed in 52% of gastrinomas in a study by Serrano et al. (2000) as an early
event, independent of the stage or localization of the disease. However, only limited studies have been conducted in relation to the role of epigenetic mechanisms in other endocrine pancreatic tumors (Table 1).

**Adrenocortical carcinomas** Adrenocortical cancer is rare (0.5–2 cases per million) though very aggressive. The majority of tumors are functional (60% of patients) (Lafemia & Brennan 2012). Non-functional tumors (40%) present as incidentalomas, frequently affect older people, and have poorer prognosis; they do not secrete any hormones or present specific symptoms (Lehmann & Wrzesinski 2012).

The first genome-wide DNA methylation profiling in adrenocortical tumors (ACTs) showed that malignant tumors have global hypomethylation compared with normal tissue or benign tumors (Rechache et al. 2012). These results are similar to those described in our group with the aggressive forms of thyroid tumors when compared with less aggressive subtypes and normal thyroid tissues (Rodriguez-Rodero et al. 2013). Rechache et al. showed that differences in methylation profile were higher between normal and primary malignant and metastatic samples than between normal and benign tumors. Moreover, 52 hypermethylated and downregulated genes in ACCs were also identified (Rechache et al. 2012). Similarly, Fonseca et al. (2012) conducted genome-wide methylation studies, finding 212 CpG islands in promoter regions that were significantly hypermethylated and that might contribute to pathology development. Barreau et al. (2013) focused their analysis on promoter CpG islands of exclusively tumoral samples (84 adrenocortical adenomas and 51 ACCs) and found that ACCs were more hypermethylated than adenomas, in accordance with previous results. They also described that ACCs could be subdivided into samples which are slightly more methylated (non-CIMP) and those that are highly methylated (CIMP).

Finally, Suh et al. (2010) have demonstrated that treatment of ACTs with decitabine (5-aza-2’-deoxycytidine) reverses DNA promoter methylation of those genes with an antitumoral function (Table 1).

**Pheochromocytomas and paraganglioma** Pheochromocytoma usually arises from the adrenal medulla. It is a catecholamine (epinephrine and norepinephrine) producing tumor arising from chromaffin cells derived from the sympathetic nervous system. Pheochromocytomas can also develop extra-adrenally (from chromaffin cells), when they are called paragangliomas. Both tumor types mostly occur sporadically, although the hereditary syndromes, MEN2a and 2b, von Hippel–Lindau disease (VHL), neurofibromatosis type 1 (NF1), and paraganglioma syndromes (PGls) 1, 2, and 3, are all associated with the development of pheochromocytoma/paraganglioma (see MEN2 section). Mutations in the proto-oncogene RET or the tumor suppressor genes VHL, NF1, SDHD, SDHC, and SDHB predispose to tumor development in these disorders. Recently, Sandgren et al. (2010) have found an increase in EZH2 expression in tumor samples when compared with normal adrenal medulla. The upregulation of this polycomb-associated methyltransferase, which specifically methylates H3K27, may be of some significance in pheochromocytoma tumorigenesis as it may contribute to silencing tumor suppressor genes (Sandgren et al. 2010). Furthermore, EZH2 overexpression has also been observed in other cancer types (Deb et al. 2013).

In paragangliomas, P16 is commonly downregulated and may contribute to tumor development. Hypermethylation of P16 is associated with a poor prognosis and seems to contribute to a reduction in the amount of the protein, as has also been observed in follicular lymphoma and laryngeal squamous cell carcinoma (Krajnovic et al. 2013, Pierini et al. 2013). However, this hypermethylation was not observed in MEN2/RET-associated paragangliomas (Kiss et al. 2008, 2013, Muscarella et al. 2008).

**Lung neuroendocrine tumors** In small-cell lung cancer (SCLC), derived from pulmonary neuroendocrine cells, genome-scale analysis of methylation changes developed in primary SCLC and SCLC cell lines by Kalari et al. (2012) found a group of 73 genes to be aberrantly methylated in more than 77% of primary SCLC tumors. Most of these genes were transcription factors or involved in processes of neuronal differentiation (NEUROD1, HAND1, ZNF423, and REST). The authors have hypothesized that inactivation of these transcription factors and proteins may cause a differentiation defect of neuroendocrine cells. Similarly, HAND1 methylation is closely associated with poor survival in patients with gastric cancer, which raises the possibility of using this gene as a potential biomarker for diagnosis or prognostic evaluation (Shi et al. 2012). In addition, other epigenetic alterations, such as loss of histone H4 acetylation at lysine16 (H4K16ac) and trimethylation at lysine 20 (H4K20me3), have also been described in this type of tumor (Li et al. 2011).

**Conclusion**

The biological relevance of epigenetic changes in pathological situations such as cancer has been widely
documented, facilitating the possibility of applying the specific findings in relation to alterations as biomarkers in various aspects of patient care. In recent years, advances in endocrine oncology have greatly improved the molecular tools available for increasing the understanding of the mechanisms involved in the development of such diseases. The field of epigenetics undoubtedly plays a role in these pathologies. Genome-wide methylation arrays have revealed the presence of certain genes with a tumor suppressor role where the promoter is aberrantly methylated, which may contribute to reduced control of angiogenesis and thus facilitate tumor spread. In this review, we have focused our attention on two primary epigenetic changes, DNA methylation, and histone modifications, both of which play an important role in gene expression and chromatin structure. The reversible nature of epigenetic modifications allows for the possibility of interventions to reverse such changes in order to treat the disease or arrest its development.

Although there are many types of endocrine tumors and, for some, only a small number of candidate genes have been analyzed, we have described some common epigenetic alterations to both hereditary and sporadic endocrine tumors in this review (Table 1), for example, the methylation of the RASSF1A gene, related to several apoptotic and cell cycle checkpoint pathways, or the hypermethylation of p16; although in both cases, the same alterations have also been found in tumor types other than endocrine. Further epigenomic studies at the genome-wide level will be needed to identify any possible specific epigenetic alterations in endocrine tumors with respect to other tumor types, and whether these changes affect specific pathways.

The epigenetic mechanisms that we have described contribute substantially, not only to understanding the progress of the pathology, but also to the search for diagnostic or prognostic markers and in the development of epigenetic drugs with possible applications in the treatment of these tumors.

**Declaration of interest**
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review reported.

**Funding**
This work was financially supported by the Fundación Asturcor (to S Rodríguez-Rodero), the Spanish National Research Council (CSIC; 200820172 to M F Fraga), Fundación Ramón Areces (to M F Fraga), the Fondo de Investigaciones Sanitarias FIS/FEDER (P11/01728 to A F Fernández), the Fondo de Investigaciones Sanitarias FIS/FEDER (PI11/01728 to A F Fernández), Fundación Mutua Madrileña (to E Menéndez-Torre), and Sociedad española de diabetes (to J L Fernández-Morera). The IUOPA was supported by the Obra Social Cajastur, Spain.

**References**


Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F & Jensen RT 2000 Alterations in the p16INK4a/Cdkn2A tumor suppressor gene in...


Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H & Wong LL 2013 2011 Histone demethylase JMJD2B coordinates H3K4/H3K9 methyl-


Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H & Wong LL 2013 2011 Histone demethylase JMJD2B coordinates H3K4/H3K9 methyl-


You S 2012 Membrane progesterone receptor as a potential progesterone receptor ERα and ESR1 expression in human breast cancer cells. *Biochimica et Biophysica Sinica 44* 14–27. (doi:10.1093/abbs/gmr100)


Received in final form 3 June 2014
Accepted 4 June 2014
Made available online as an Accepted Preprint 4 June 2014